🚀 VC round data is live in beta, check it out!
Binex Valuation Multiples
Discover revenue and EBITDA valuation multiples for Binex and similar public comparables like S Biomedics, Reig Jofré, Transgene, Arcturus Therapeutics and more.
Binex Overview
About Binex
Binex Co Ltd is engaged in manufacturing and distribution of pharmaceutical products. The key products include gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as an ointment, creams, and others. It also manufactures biomedicines and raw materials. Its other business operation involved contract development and manufacturing business for other companies. The company invests in some bio ventures that develop biomedicines.
Founded
1985
HQ
Employees
N/A
Website
Financials (LTM)
EV
$309M
Binex Financials
Binex reported last 12-month revenue of $119M and EBITDA of $3M.
In the same LTM period, Binex generated $33M in gross profit, $3M in EBITDA, and had net loss of ($1M).
Revenue (LTM)
Binex P&L
In the most recent fiscal year, Binex reported revenue of $114M and EBITDA of $9M.
Binex expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $119M | XXX | $114M | XXX | XXX | XXX |
| Gross Profit | $33M | XXX | $30M | XXX | XXX | XXX |
| Gross Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBITDA | $3M | XXX | $9M | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | 8% | XXX | XXX | XXX |
| EBIT Margin | (1%) | XXX | (3%) | XXX | XXX | XXX |
| Net Profit | ($1M) | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | (1%) | XXX | (2%) | XXX | XXX | XXX |
| Net Debt | — | — | $50M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Binex Stock Performance
Binex has current market cap of $257M, and enterprise value of $309M.
Market Cap Evolution
Binex's stock price is $8.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $309M | $257M | 0.7% | XXX | XXX | XXX | $-0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBinex Valuation Multiples
Binex trades at 2.6x EV/Revenue multiple, and 95.5x EV/EBITDA.
EV / Revenue (LTM)
Binex Financial Valuation Multiples
As of April 18, 2026, Binex has market cap of $257M and EV of $309M.
Equity research analysts estimate Binex's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Binex has a P/E ratio of (184.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $257M | XXX | $257M | XXX | XXX | XXX |
| EV (current) | $309M | XXX | $309M | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 95.5x | XXX | 36.1x | XXX | XXX | XXX |
| EV/EBIT | (249.9x) | XXX | (102.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 9.5x | XXX | 10.1x | XXX | XXX | XXX |
| P/E | (184.5x) | XXX | (119.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (9.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Binex Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Binex Margins & Growth Rates
Binex's revenue in the last 12 month grew by 17%.
Binex's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Binex's rule of X is 47% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Binex Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | 208% | XXX | (13%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 47% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Binex Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Binex | XXX | XXX | XXX | XXX | XXX | XXX |
| S Biomedics | XXX | XXX | XXX | XXX | XXX | XXX |
| Reig Jofré | XXX | XXX | XXX | XXX | XXX | XXX |
| Transgene | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcturus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Flerie | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Binex M&A Activity
Binex acquired XXX companies to date.
Last acquisition by Binex was on XXXXXXXX, XXXXX. Binex acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Binex
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBinex Investment Activity
Binex invested in XXX companies to date.
Binex made its latest investment on XXXXXXXX, XXXXX. Binex invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Binex
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Binex
| When was Binex founded? | Binex was founded in 1985. |
| Where is Binex headquartered? | Binex is headquartered in South Korea. |
| Who is the CEO of Binex? | Binex's CEO is Hyuk-jong Lee. |
| Is Binex publicly listed? | Yes, Binex is a public company listed on Korea Exchange. |
| What is the stock symbol of Binex? | Binex trades under 053030 ticker. |
| When did Binex go public? | Binex went public in 2001. |
| Who are competitors of Binex? | Binex main competitors are S Biomedics, Reig Jofré, Transgene, Arcturus Therapeutics. |
| What is the current market cap of Binex? | Binex's current market cap is $257M. |
| What is the current revenue of Binex? | Binex's last 12 months revenue is $119M. |
| What is the current revenue growth of Binex? | Binex revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Binex? | Current revenue multiple of Binex is 2.6x. |
| Is Binex profitable? | Yes, Binex is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Binex? | Binex's last 12 months EBITDA is $3M. |
| What is Binex's EBITDA margin? | Binex's last 12 months EBITDA margin is 3%. |
| What is the current EV/EBITDA multiple of Binex? | Current EBITDA multiple of Binex is 95.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.